Ashwani Verma
Stock Analyst at UBS
(2.19)
# 2,728
Out of 4,876 analysts
69
Total ratings
40.82%
Success rate
-1.54%
Average return
Main Sectors:
Stocks Rated by Ashwani Verma
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $24 → $23 | $16.83 | +36.66% | 9 | Jun 26, 2025 | |
| ALKS Alkermes | Upgrades: Buy | $33 → $42 | $28.97 | +44.98% | 5 | Jun 17, 2025 | |
| INCY Incyte | Maintains: Neutral | $61 | $70.24 | -13.15% | 1 | Jun 3, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Buy | $137 → $152 | $126.54 | +20.12% | 8 | May 6, 2025 | |
| CYTK Cytokinetics | Maintains: Neutral | $47 → $41 | $33.47 | +22.50% | 5 | May 2, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Buy | $55 → $48 | $31.89 | +50.54% | 2 | Apr 28, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Buy | $25 → $22 | $22.29 | -1.30% | 4 | Apr 28, 2025 | |
| CHRS Coherus Oncology | Maintains: Neutral | $1.5 → $1.05 | $0.74 | +41.55% | 5 | Apr 24, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Buy | $145 → $179 | $108.76 | +64.58% | 6 | Mar 7, 2025 | |
| EXEL Exelixis | Maintains: Neutral | $30 → $34 | $43.31 | -21.50% | 2 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $14 | $9.15 | +53.09% | 2 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $415 → $475 | $286.53 | +65.78% | 4 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $106 → $114 | $64.66 | +76.31% | 2 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $55 → $54 | $14.41 | +274.74% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $107 → $105 | $105.10 | -0.10% | 2 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 | $35.59 | -21.33% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $76 → $81 | $35.01 | +131.36% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $7 | $88.78 | -92.12% | 1 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $9.10 | +31.87% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $0.55 | +2,651.28% | 1 | Oct 11, 2022 |
Teva Pharmaceutical Industries
Jun 26, 2025
Maintains: Buy
Price Target: $24 → $23
Current: $16.83
Upside: +36.66%
Alkermes
Jun 17, 2025
Upgrades: Buy
Price Target: $33 → $42
Current: $28.97
Upside: +44.98%
Incyte
Jun 3, 2025
Maintains: Neutral
Price Target: $61
Current: $70.24
Upside: -13.15%
Neurocrine Biosciences
May 6, 2025
Maintains: Buy
Price Target: $137 → $152
Current: $126.54
Upside: +20.12%
Cytokinetics
May 2, 2025
Maintains: Neutral
Price Target: $47 → $41
Current: $33.47
Upside: +22.50%
Harmony Biosciences Holdings
Apr 28, 2025
Maintains: Buy
Price Target: $55 → $48
Current: $31.89
Upside: +50.54%
ACADIA Pharmaceuticals
Apr 28, 2025
Maintains: Buy
Price Target: $25 → $22
Current: $22.29
Upside: -1.30%
Coherus Oncology
Apr 24, 2025
Maintains: Neutral
Price Target: $1.5 → $1.05
Current: $0.74
Upside: +41.55%
Jazz Pharmaceuticals
Mar 7, 2025
Upgrades: Buy
Price Target: $145 → $179
Current: $108.76
Upside: +64.58%
Exelixis
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $34
Current: $43.31
Upside: -21.50%
Jan 13, 2025
Maintains: Buy
Price Target: $22 → $14
Current: $9.15
Upside: +53.09%
Jan 8, 2025
Maintains: Buy
Price Target: $415 → $475
Current: $286.53
Upside: +65.78%
Dec 10, 2024
Maintains: Buy
Price Target: $106 → $114
Current: $64.66
Upside: +76.31%
Aug 13, 2024
Maintains: Buy
Price Target: $55 → $54
Current: $14.41
Upside: +274.74%
Aug 6, 2024
Maintains: Buy
Price Target: $107 → $105
Current: $105.10
Upside: -0.10%
Jun 3, 2024
Downgrades: Neutral
Price Target: $28
Current: $35.59
Upside: -21.33%
Mar 18, 2024
Maintains: Buy
Price Target: $76 → $81
Current: $35.01
Upside: +131.36%
Aug 7, 2023
Maintains: Buy
Price Target: $11 → $7
Current: $88.78
Upside: -92.12%
Nov 10, 2022
Upgrades: Neutral
Price Target: $9 → $12
Current: $9.10
Upside: +31.87%
Oct 11, 2022
Initiates: Buy
Price Target: $15
Current: $0.55
Upside: +2,651.28%